Interleukins in chronic liver disease: lessons learned from experimental mouse models
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Interleukins represent a class of immunomodulatory cytokines, small intercellular signaling proteins, that are critically involved in the regulation of immune responses. They are produced in large amounts by various cell types during inflammatory reactions, and the balance of cytokines determines the outcome of an immune response. Therefore, cytokines are regarded as interesting therapeutic targets for the treatment of patients with liver diseases. Mouse models provide a good tool for in vivo studies on cytokine function, as human and mouse cytokines share many homologies. Sophisticated mouse models either mimicking distinct pathological conditions or targeting cytokines and cytokine-signaling pathways in the liver or even in distinct cellular compartments have provided enormous insight into the different functions of interleukins during hepatic inflammation. Interleukins may have pro- as well as anti-inflammatory functions in chronic liver diseases, some interleukins even both, dependent on the inflammatory stimulus, the producing and the responding cell type. IL-17, for example, promotes hepatic fibrogenesis through activation of hepatic stellate cells and facilitates development of liver cancer through recruitment of myeloid-derived suppressor cells. IL-22, on the other hand, protects from development of fibrosis or steatohepatitis. IL-12 balances T-helper (Th)-1 and Th2 cell responses in infectious disease models. IL-13 and IL-33, two cytokines related to Th2 cells and innate lymphoid cells, promote fibrotic responses in the liver. IL-10 is the prototypic anti-inflammatory interleukin with tissue-protective functions during chronic liver injury and fibrogenesis. Despite its critical role for inducing the acute-phase response in the liver, IL-6 signaling is protective during fibrosis progression, but promotes hepatocellular carcinoma. Experimental studies in mice help to define the exact influence of a specific cytokine on the outcome of chronic liver diseases and to identify useful therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 1×
“16 Consistently, IL-6-deficient or TNF receptor-deficient mice displayed reduced hepatocarcinogenesis after DEN treatment and an HFD, which was also accompanied by reduced expression of STAT3.”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 2×
“46 IL-17 directly induced production of collagen and α -smooth- muscle actin in HSCs through activation of STAT3, as STAT3 − / − HSCs failed to produce collagen upon IL-17 treat-ment and STAT3-deficient mice displayed less fibrosis development compared to WT mice.”
BackgroundChiaramonte, M. G., Donaldson, D. D., Cheever, A. W., & Wynn, T. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7325 · Cited by 603 · cited 2×
“39–41 IL-13-deficient mice or mice treated with an IL-13 inhibitor developed significantly less liver fibrosis than mice with intact IL-13 signaling.”
Interleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic Fibrosis
Mchedlidze, T., Waldner, M., Zopf, S., Walker, J., Rankin, A. L., Schuchmann, M., Voehringer, D., McKenzie, A. N. J., Neurath, M. F., Pflanz, S., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.018 · Cited by 502
Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice
Kong, X., Feng, D., Wang, H., Hong, F., Bertola, A., Wang, F.-S., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.25744 · Cited by 448
Evolutionary divergence and functions of the human interleukin (IL) gene family
Brocker, C., Thompson, D., Matsumoto, A., Nebert, D. W., & Vasiliou, V. (2010) · Human Genomics · doi:10.1186/1479-7364-5-1-30 · Cited by 368
STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6
Zhang, D., Sun, M., Samols, D., & Kushner, I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9503 · Cited by 309 · cited 1×
“10 In experimental models of liver injury, mice deficient for the gp130 receptor in hepatocytes showed an abolished acute-phase response and an increased susceptibility to lipopolysaccharide-induced liver failure or to bacterial infections.”
BackgroundIncreased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice
Kovalovich, K., DeAngelis, R. A., Li, W., Furth, E. E., Ciliberto, G., & Taub, R. (2000) · Hepatology · doi:10.1002/hep.510310123 · Cited by 298 · cited 1×
“Kovalovich et al showed that IL-6-deficient mice display increased hepatocyte injury and apoptosis after just a single CCl 4 injection, which resulted in higher liver fibrosis upon chronic treatment.(18) Similar results were obtained in a different study, where deletion of gp130 in nonparenchymal liver cells also resu…”
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., Han, X., Peng, Y., Chen, X., Shen, L., et al. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04471.x · Cited by 294
Cited by
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Self-citationOrgan and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Self-citationThe Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis
Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., & Keswani, S. G. (2020) · Advances in Wound Care · doi:10.1089/wound.2019.1032 · Cited by 433
Fibrosis Related Inflammatory Mediators: Role of the IL‐10 Cytokine Family
Sziksz, E., Pap, D., Lippai, R., Béres, N. J., Fekete, A., Szabó, A. J., & Vannay, Á. (2015) · Mediators of Inflammation · doi:10.1155/2015/764641 · Cited by 265
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
“carcinogenesis induction by diethylnitrosamine (DEN) treatment [61].”
Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
Schon, H.-T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00033 · Cited by 97
“Interleukin-10 is the prototype of an anti-inflammatory cytokine that suppresses inflammatory reactions and can attenuate excessive tissue scarring (Hammerich and Tacke, 2014).”
BackgroundSelf-citationThe Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities
Binatti, E., Gerussi, A., Barisani, D., & Invernizzi, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126649 · Cited by 62
“IL-6 dependent signaling in the liver is critical for the induction of the acute-phase response [29].”
BackgroundRemmler, J., Schneider, C., Treuner-Kaueroff, T., Bartels, M., Seehofer, D., Scholz, M., Berg, T., & Kaiser, T. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.017 · Cited by 56
Metadata
- Authors
- Tacke, F., & Hammerich, L.
- Venue
- Clinical and Experimental Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2014-09
- Volume
- 7
- Pages
- 297
- ISSN
- 1178-7023 (ISSN-L)
- OpenAlex
- W2093855402
- Cited by
- 120
- References
- 16
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.